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Background:  Maternal  alcohol  use  during  pregnancy  causes  a continuum  of  long-lasting  disabilities
in  the  offspring,  commonly  referred  to as fetal  alcohol  spectrum  disorder  (FASD).  Attention-
deﬁcit/hyperactivity  disorder  (ADHD)  is possibly  the  most  common  behavioral  problem  in children  with
FASD and  devising  strategies  that  ameliorate  this  condition  has  great  clinical  relevance.  Studies  in rodent
models  of  ADHD  and  FASD  suggest  that impairments  in  the  cAMP  signaling  cascade  contribute  to  the
hyperactivity  phenotype.  In  this  work,  we  investigated  whether  the  cAMP  levels  are  affected  in  a long-
lasting  manner  by ethanol  exposure  during  the  third  trimester  equivalent  period  of human  gestation  and
whether  the  acute  administration  of  the  PDE1  inhibitor  vinpocetine  ameliorates  the ethanol-induced
hyperactivity.
Methods:  From  postnatal  day  (P)  2 to P8, Swiss  mice  either  received  ethanol  (5 g/kg  i.p.)  or  saline  every
other  day.  At  P30, the  animals  either  received  vinpocetine  (20  mg/kg  or 10  mg/kg  i.p.) or vehicle 4 h before
being  tested  in  the  open  ﬁeld.  After  the  test, frontal  cerebral  cortices  and  hippocampi  were  dissected  and
collected  for  assessment  of  cAMP  levels.
Results:  Early  alcohol  exposure  signiﬁcantly  increased  locomotor  activity  in  the  open  ﬁeld  and  reduced
cAMP  levels  in  the  hippocampus.  The  acute  treatment  of  ethanol-exposed  animals  with  20 mg/kg  of
vinpocetine  restored  both  their  locomotor  activity  and  cAMP  levels  to  control  levels.
Conclusions:  These  data  lend  support  to  the  idea  that  cAMP  signaling  system  contribute  to  the  hyperac-
tivity  induced  by developmental  alcohol  exposure  and  provide  evidence  for  the potential  therapeutic  use
of vinpocetine  in  FASD.. Introduction
Maternal ethanol use during pregnancy causes a continuum
f long-lasting disabilities in the offspring (Riley and McGee,
005) commonly referred to as fetal alcohol spectrum disorder
FASD). It is estimated that the prevalence of FASD in school chil-
ren may  be as high as 2–5% in developed countries (May  et al.,
009). Several neurobehavioral problems can be observed in FASD
Kelly et al., 2000; Kodituwakku, 2009; Riley and McGee, 2005),
nd attention-deﬁcit/hyperactivity disorder (ADHD) is possibly the
ost commonly observed behavioral problem (Bhatara et al., 2006;
urd et al., 2003; Doig et al., 2008). It was estimated that as many
 Supplementary Materials showing mortality rates and open ﬁeld activity can be
ound by accessing the online version of this paper at http://dx.doi.org.
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as 41% of children with FASD have a comorbid ADHD diagnosis
(Bhatara et al., 2006), while in studies considering children with
fetal alcohol syndrome (FAS), which represents the most severe
outcome of prenatal ethanol exposure (Goodlett et al., 2005; Riley
and McGee, 2005), this percentage ranges from 73% (Burd et al.,
2003) to 95% (Fryer et al., 2007).
Although the three main symptoms of ADHD, impulsiveness,
inattentiveness and hyperactivity, have been modeled in rodents
(Sagvolden et al., 2005), hyperactivity is the most frequently stud-
ied by far. Murine hyperactivity has been usually assessed in
the open ﬁeld test, which estimates ambulatory movements on
a wide surface. Despite its simplicity, the measure of ambula-
tion has proven to be a useful tool in studies designed to predict
aspects of behavior, genetics, and neurobiology of ADHD (Lalonde
Open access under the Elsevier OA license. and Strazielle, 2009; Sagvolden et al., 2005). Locomotor hyper-
activity is a pivotal behavioral trait observed in several inbred
strains, knockouts, and transgenic rodents used as models of ADHD
(Russell, 2007; Sagvolden et al., 2005). In FASD rodent models,
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ocomotor hyperactivity has been consistently described in animals
xposed to ethanol during the third trimester equivalent period of
uman gestation (Kelly et al., 1987; Melcer et al., 1994; Riley et al.,
993; Slawecki et al., 2004; Thomas et al., 2001, 2007), which, in
ice and rats, corresponds to the ﬁrst 10-day period after birth.
uring this period (also called “brain growth spurt”), there is a
urge in brain growth characterized by neurogenesis, dendritic
rborization, synaptogenesis and the migration of multiple neu-
onal populations (Bandeira et al., 2009; Dobbing and Sands, 1979)
nd some brain regions such as the frontal cortex and the hip-
ocampus are very sensitive to ethanol (Gil-Mohapel et al., 2010;
lney et al., 2002b).  Damage to neuronal circuits in these regions
ay  lead to functional impairments in neurotransmission systems,
hus triggering the emergence of hyperactivity (Goto and Grace,
007).
Studies in rodents have suggested that impairments in the
econd messenger cAMP signaling pathway contribute to the
yperactivity phenotype in animals that are in a hypocate-
holaminergic state (Paine et al., 2009; Pascoli et al., 2005;
ussell, 2003). In the cAMP-regulated cascade (Medina, 2011b),
he activation of adenylyl cyclase by the activation of dopamine,
oradrenaline or NMDA receptors leads to the generation of intra-
ellular cAMP that, in turn, activates protein kinases such as
AMP-dependent protein kinase A (PKA). PKA phosphorylates tran-
cription factors such as CREB (cAMP response element binding
rotein), and SRF (serum response factor), leading to the expres-
ion of genes that modulate the neuronal excitability and plasticity
ithin brain regions such as the frontal cortex and the hippocam-
us (Goto and Grace, 2007; Gurden et al., 1999, 2000). The deletion
f SRF in dopaminoceptive neurons of mice causes a marked loco-
otor hyperactivity (Parkitna et al., 2010). The PKA inhibition
ithin the medial prefrontal cortex of rats produces inattention and
yperactivity (Paine et al., 2009). Interestingly, ethanol exposure
uring development can alter several key factors in the cAMP/PKA
ignaling pathway (Conway and Garbouzova, 1996; Kumada et al.,
010; Maas et al., 2005), with long-lasting effects. Neonatal ethanol
xposure promotes a reduction in CREB phosphorylation in the
dult mice hippocampus (Roberson et al., 2009) and in the visual
ortex of ferrets (Krahe et al., 2009). The overexpression of SRF by
 Sindbis viral vector long after the period of ethanol exposure
estores the ocular dominance plasticity in the visual cortex of a
erret model of FASD (Paul et al., 2010). The use of pharmacological
r molecular tools to strengthen this signaling pathway opens up a
reat therapeutic possibility. Particularly, vinpocetine, a derivative
f the Vinca minor alkaloid vincamine, is a phosphodiesterase type
 (PDE1) inhibitor that has been successfully used for the treat-
ent of neurobehavioral problems observed in animal models of
ASD (Filgueiras et al., 2010; Krahe et al., 2009; Medina et al., 2006;
edina, 2011b). The PDE1 inhibition prevents the breakdown of
AMP to 5′-AMP, maintaining activation of protein kinases and
ranscription factors CREB and SRF (Krahe et al., 2009; Medina and
rahe, 2008; Paul et al., 2010).
Considering that impairments in the cAMP/PKA signaling sys-
em may  contribute to the hyperactivity observed in FASD, here
e investigated whether the acute administration of the PDE1
nhibitor vinpocetine ameliorates the hyperactivity observed in
ice exposed to ethanol during the third trimester equivalent of
uman gestation. Additionally, we investigated whether the cAMP
evels in the hippocampus and frontal cortex of adolescent mice are
ffected by neonatal exposure to ethanol.
. Methods.1. Animal treatment
This study was  conducted under institutional approval (protocol#:
EUA/040/2010) of the Universidade do Estado do Rio de Janeiro. All experi-pendence 119 (2011) 81– 87
ments were carried out in compliance with the Guide for the Care and Use of
Laboratory Animals as adopted and promulgated by the National Institutes of
Health. Subjects were Swiss mice that were bred and maintained in our laboratory
on a 12:12 h light/dark cycle (lights on: 2:00, lights off: 14:00) at a constant
temperature (22 ◦C). Access to food and water was unrestricted. Original breeding
stock was  obtained from Instituto Vital Brazil (Rio de Janeiro, RJ, Brazil).
From P2 to P8 (P1 = birth day), 104 animals from 9 litters received a single injec-
tion of ethanol (5 g/kg i.p., 25% in saline solution, ETOH group) every other day and
103  animals from 9 litters received an equivalent volume of saline solution (26 L/g,
SAL  group) every other day. The treatment of entire litters with ethanol or saline was
chosen based on previous data obtained in our laboratory which show that the mor-
tality rate of ethanol-treated pups using this protocol is signiﬁcantly lower than that
of  pups from litters in which half of the animals receive ethanol and the other half
receive saline (Supplementary Material, A). The dose of ethanol was chosen based on
previous studies (Filgueiras et al., 2009), which show that it generates blood ethanol
concentrations (BECs) within the range that a human fetus would be exposed to after
maternal ingestion of a moderate to heavy dose of ethanol (Eckardt et al., 1998).
Treatment on alternate days was chosen since it mimics ‘binge’ drinking in humans,
which is associated with severe neurobehavioral deﬁcits (Maier and West, 2001). In
order to minimize the risk of injury to internal organs, a 28-gauge needle was care-
fully inserted to just penetrate the abdominal wall and reach the peritoneal cavity.
Leakage from the injection site was minimized by slowly withdrawing the needle
from the abdominal cavity.
At weaning (P21), animals from the same litter were separated by sex and
housed in groups of 2–5 mice by cage. From the initial sample of mice treated with
ethanol or saline, only 149 (80 ethanol-injected and 69 saline-injected) were used
for  the behavioral analysis. The other 58 animals (24 ethanol-injected and 34 saline-
injected), which were used in other studies (ETOH: n = 11; SAL: n = 29) or died (ETOH:
n  = 13, 12.5% mortality rate; SAL: n = 5, 4.9% mortality rate) during treatment, were
considered only to estimate the mortality rate after ethanol or saline treatment. The
mortality rate was calculated separately for each group by the number of animals
that died until P30/total number of animals injected at P2. At P30, the animals were
randomly assigned within each litter to receive treatment with vinpocetine (Vp)
20  mg/kg (i.p., in dimethylsulfoxide, DMSO, 0.5%, w/v), Vp10 mg/kg, or an equiv-
alent  volume of DMSO. Accordingly, we had 6 treatment groups: SAL + DMSO (14
females and 19 males), SAL + Vp10 mg (8 females and 8 males), SAL + Vp20 mg (10
females and 10 males), ETOH + DMSO (11 females and 13 males), ETOH + Vp10 mg
(13  females and 14 males), ETOH + Vp20 mg (14 females and 15 males). Vinpocetine
and DMSO were purchased from Sigma–Aldrich (St. Louis, MO). Injections were car-
ried out 4 h before the behavioral test. This time-interval was  chosen because it is
close to the peak of increase in cAMP levels induced by vinpocetine administration
in mice (unpublished data). Furthermore, we have demonstrated that vinpocetine
4  h before Morris water maze testing improved learning and memory deﬁcits in rats
early exposed to ethanol (Filgueiras et al., 2010).
2.2. Open ﬁeld test
The open ﬁeld arena consisted of a polypropylene box
(37.6 cm × 30.4 cm × 17 cm) in which the ﬂoor was divided into 16 same-
sized rectangles (7.6 cm × 9.4 cm), 12 peripheral and 4 central. The experiments
were conducted under bright white light illumination during the dark part of the
daily cycle, 1–2 h after its onset. Each mouse was  individually placed in the center
of  the arena. Behaviors in the open ﬁeld were recorded for 10 min  (divided into
1  min  intervals) with an overhead video camera. At the end of the session, the ﬂoor
and walls were washed with odorless liquid soap, rinsed thoroughly with tap water
and  dried with a disposable paper towel. Recorded images of the tests were used
to  analyze behavior. The observer was blind regarding the experimental treatment
of  the animals. The ambulation was quantiﬁed on the basis of the number of
rectangles crossed by the animals (Filgueiras et al., 2009). Mice had to place all four
legs on a given rectangle for a crossing to be counted. The following ambulation
variables were evaluated: ambulation in the center (C), ambulation in the periphery
(Pe), C/Pe ratio and total ambulation (C + Pe). In addition, considering that direct
comparisons between the activity in the center and in periphery can be inﬂuenced
by the fact that the number of rectangles in the periphery is greater than that in the
center, the rectangles crossed in the center and in the periphery were respectively
divided by 4 (C/4) and 12 (Pe/12).
2.3. Blood ethanol concentration (BEC)
A  separate group of mice was  injected with ethanol or saline as described above.
One or 2 h after the second injection (at P4), animals were decapitated and blood was
collected (ethanol – 1 h: n = 13, 2 h: n = 9; saline – 1 h: n = 10, 2 h: n = 6). Blood was
centrifuged at 2000 rpm for 5 min and the supernatant stored at 4 ◦C until assayed.
BEC was  assessed using an enzymatic kit (Alcohol Reagent Set, Pointe Scientiﬁc Inc.,
Michigan, USA) in accordance with the manufacturer’s recommendations.2.4. cAMP levels
After the test, 60 animals (at least 7 per group) were sacriﬁced by cervical dis-
location. Frontal cerebral cortices (approximately the rostral third of the cerebral
F. Nunes et al. / Drug and Alcohol De
Table 1
Mean litter weights (g).
Postnatal day
P2 P4 P6 P8
SAL 1.9 ± 0.9 2.7 ± 0.1 3.6 ± 1.6 4.6 ± 0.3
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tETOH 2.1 ± 1.9 2.9 ± 0.1 3.8 ± 1.8 4.7 ± 0.2
alues represent means ± SEM.
all) and hippocampi were immediately dissected and incubated for 1 h at 37 ◦C
n  minimum essential medium (MEM)  buffered with 20 mM HEPES at pH 7.3 and
ontaining 100 mM ascorbic acid, 100 mM pargyline and 0.5 mM Rolipram (Sigma
hemical Co., St. Louis, MO,  USA). After incubation, the reaction was interrupted
y  the addition of TCA to 10% (ﬁnal concentration). cAMP was  puriﬁed by remov-
ng  trichloroacetic acid and endogenous interfering compounds from supernatant
olution, using an ion exchange column of AGSOW-X4 (200–400 mesh, hydrogen
orm, Bio-Rad, Rio de Janeiro, Brazil), previously washed and equilibrated with H2O
Matsuzawa and Nirenberg, 1975). Cyclic AMP  concentrations of puriﬁed samples
ere  determined by a protein binding assay described previously (de Mello et al.,
982; Gilman, 1970). cAMP levels were normalized to protein levels, assayed by the
owry method.
.5. Statistical analyses
Data are compiled as means and standard errors. In order to minimize the
nﬂuence of litter effects, for all analyses, we  considered the average of values
rom male and female mice of the same litter instead of using individual values
Wainwright, 1998). Separate univariate analyses of variance (uANOVA) were per-
ormed for weight data at P30, for cAMP levels in each region (frontal cerebral cortex
r  hippocampus) and for comparisons involving ambulation in the center and in
he periphery of the open ﬁeld. Repeated measures analyses of variance (rANOVA)
ere performed for both body weight data (postnatal; day as the within-subjects
actor) and open ﬁeld data (time-interval as the within-subjects factor). Neona-
al  exposure (ETOH or SAL), treatment at P30 (Vp10 mg, Vp20 mg  or DMSO) and
ender were used as between-subject factors for both uANOVAs and rANOVAS.
egarding rANOVAs, for simplicity, we report results based only on the averaged
nivariate F tests. Whenever the sphericity assumption was  violated, we  used the
reenhouse–Geisser correction, which adjusts the degrees of freedom, in order to
void Type I errors. Signiﬁcance was assumed at the level of P < 0.05 (two-tailed). In
ll  cases, individual group differences were evaluated post-hoc by Fisher’s Protected
east Signiﬁcant Difference (FPLSD).
. Results
.1. BEC, survival rate and body weight gain
In the ethanol-injected group, BEC 1 and 2 h after injection
ere 316.2 ± 9.6 and 321.4 ± 6.5 mg/dL, respectively. In the saline-
njected group, these levels were 2.4 ± 3.1 and 7.0 ± 4.7 mg/dL. The
ajority of the animals survived saline and ethanol i.p. injections.
urvival rates were 87.5% (n = 91) in the ethanol-injected group and
5.1% (n = 98) in the saline-injected group. The difference between
roups did not reach statistical signiﬁcance (Fisher’s Exact Test,
 = 0.56).
Offspring weights during the injection period are shown in
able 1. The mean litter weights increased signiﬁcantly from P2
o P8 [rANOVA, F(1.2,18.7) = 600.6; P < 0.001]. From P2 to P8, no
ifferences were observed between ethanol-injected and saline-
njected groups regarding weight gain or absolute weight. At
30 (open ﬁeld testing day), no differences in body weight were
bserved between ethanol (21.9 ± 0.6 g) or saline (21.6 ± 0.6 g)
njected animals [uANOVA, F(1,35) = 0.1; P = 0.75]. The mean litter
eights of males (22.7 ± 0.6 g) was signiﬁcantly higher than that of
emales (20.8 ± 0.6 g) [uANOVA, F(1,35) = 4.6; P < 0.05]. There was
o interaction between gender and neonatal treatment [uANOVA,
(1,35) = 0.01; P = 0.94]..2. Open ﬁeld data
For all animals collapsed across conditions, the ambulation in
he periphery (89.5 ± 3.7) was signiﬁcantly greater than in thependence 119 (2011) 81– 87 83
center (19.0 ± 1.3) [uANOVA, F(1,148) = 768.2; P < 0.001] conﬁrm-
ing that mice avoid open areas (Prut and Belzung, 2003). When
ambulation values were corrected for the corresponding number of
rectangles in the periphery (7.5 ± 0.3) and in the center (4.8 ± 0.3),
this difference remained signiﬁcant [uANOVA, F(1,148) = 730.1;
P < 0.001]. Considering that activity in the center has been largely
used as an indicator of anxiety (Prut and Belzung, 2003), the ambu-
lation in the center was analyzed separately.
Regarding total ambulation (C + Pe), treatment with vinpoce-
tine signiﬁcantly ameliorated the hyperactivity induced by early
ethanol exposure in a dose-dependent way  [rANOVA: Neonatal
Treatment × Treatment at P30 interaction, F(2,63) = 3.6; P < 0.05].
As depicted in Fig. 1, the ambulatory activity of the ETOH + DMSO
group was ∼29% higher than that of the SAL + DMSO group
(FPLSD, P < 0.05), ∼45% higher than that of the SAL + Vp10 mg
group (FPLSD, P < 0.05) and ∼49% higher than that of the
ETOH + Vp20 mg  group (FPLSD, P < 0.01). The dose-dependent ame-
lioration of hyperactivity elicited by vinpocetine was evidenced by
the fact that the ETOH + Vp20 mg  group had an average locomotor
activity similar to that of the SAL + DMSO group while, distinc-
tively, the ETOH + Vp10 mg  group did not differ from both the
SAL + DMSO and the ETOH + DMSO groups. No signiﬁcant differ-
ences were observed between SAL + Vp20 mg  and ETOH + DMSO
as well as between males and females (P > 0.05 in all pairwise
comparisons).
For both ambulation in the center and C/Pe ratio data, increases
in values were observed along the 10 time-intervals [rANOVA:
ambulation in the center, F(6.3,393.1) = 3.3; P < 0.01 and C/Pe ratio,
F(3.6,120.1) = 2.7; P < 0.05]. However, for these two variables, no dif-
ferences were observed between groups. Furthermore, no effects
or interactions regarding gender, neonatal exposure and treatment
at P30 were observed. Taken together, these results suggest that
the ethanol-injected mice are hyperactive while maintaining nor-
mal  levels of anxiety. In addition, the treatment with vinpocetine
did not differentially affect the anxiety levels of ethanol- or saline-
injected animals.
Regarding ambulation in the periphery, the results were simi-
lar to those described for total ambulation (C + Pe) (Supplementary
Material, B).
3.3. cAMP data
Considering that the vinpocetine treatment effectively ame-
liorated hyperactivity only at the 20 mg/kg dose, we did not
conduct the cAMP assays on the vinpocetine 10 mg/kg sam-
ples. As expected, treatment with vinpocetine increased the
levels of cAMP by approximately 60% both in the hippocampus
[uANOVA: F(1,21) = 69.8; P < 0.001] and in the cortex [uANOVA:
F(1,21) = 43.8; P < 0.001]. In the hippocampus, neonatal exposure
to ethanol reduced cAMP levels [uANOVA, F(1,21) = 63.9; P < 0.001]
and treatment with vinpocetine signiﬁcantly restored cAMP lev-
els [uANOVA, F(1,21) = 9.1; P < 0.01]. Accordingly, cAMP levels
in the ETOH + DMSO group were signiﬁcantly lower than those
observed in both SAL + DMSO (∼33%) and ETOH + Vp20 mg  (∼31%)
groups, which, in turn, did not differ from each other (Fig. 2A).
No signiﬁcant differences were observed between males and
females.
In the cortex, cAMP levels in saline-exposed animals
(SALINE + DMSO and SAL + Vp20 mg  combined sample) were ∼17%
higher than those of the ethanol-exposed ones (ETOH + DMSO
and ETOH + Vp20 mg  combined sample) [uANOVA, F(1,21) = 7.0;
P < 0.05]. However, no differences were observed between
ETOH + DMSO and SAL + DMSO groups when they were analyzed
separately (Fig. 2B). No signiﬁcant differences were observed
between males and females.
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Pig. 1. Mean (±SEM) of total ambulation (C + Pe) in the open ﬁeld of mice exposed to
0  mg/kg (Vp10 mg), vinpocetine 20 mg/kg (Vp20 mg)  or vehicle (DMSO) at P30. No
ith  vehicle solution and that the treatment with 20 mg/kg of vinpocetine restores
. Discussion
In the present study, we show that ethanol exposure during
he third trimester equivalent of human gestation signiﬁcantly
ncreases locomotor activity in the open ﬁeld. This result is in accor-
ance with other studies in rodents exposed to ethanol during
his period. Importantly, in these studies, the hyperactivity was
escribed during the dark period irrespective of whether the ani-
als were tested under dim red light (Melcer et al., 1994; Riley et al.,
993), bright light illumination (Slawecki et al., 2004) or with the
ights off (Thomas et al., 2001). We  also show that ethanol reduces
AMP levels and that the inhibition of the phosphodiesterase type 1
y vinpocetine signiﬁcantly ameliorates hyperactivity and restores
AMP levels to control levels. Importantly, vinpocetine treatment
as carried out long after the period of ethanol exposure, in a
eriod equivalent to infancy/adolescence in humans. Our ﬁndings
ay  be relevant from a clinical standpoint since they open up the
ossibility for treating juveniles when prevention fails.
During the brain growth spurt, ethanol triggers massive apo-
totic neurodegeneration (Ikonomidou et al., 2000; Olney et al.,
002a). It has been assumed that neuronal loss is the main cause
f reduced brain mass and lifelong neurobehavioral disturbances
esulting from early ethanol exposure (Han et al., 2005; Medina,
011a; Wozniak et al., 2004). Particularly, the locomotor hyper-
ctivity observed in rodents exposed to ethanol during the brain
rowth spurt has been associated with an increase in neuronal
eath in cortex and hippocampus (Ieraci and Herrera, 2006). How-
ver, in addition to apoptotic neurodegeneration, early ethanol
xposure may  lead to persistent impairments in the function
f surviving neurons (Medina, 2011a).  Our ﬁnding that neona-
al ethanol exposure reduced pubertal cAMP levels corroborates
he idea that the cAMP/PKA signaling cascade may  present long-
asting impairments in animals exposed to ethanol during the brain
rowth spurt. In addition, that vinpocetine restores cAMP levels in
thanol-exposed mice and ameliorates ethanol-induced hyperac-
ivity suggests that an impairment in the second messenger cAMP
ignaling pathway plays a key role in generating the hyperactiv-
ty phenotype observed in FASD animal models (Paine et al., 2009;
ascoli et al., 2005; Russell, 2003).
Intracellular levels of cAMP are determined by the balance
etween its synthesis and breakdown. It is synthesized from ATP
y adenylyl cyclase in response to hormones, neurotransmitters
nd various environmental stimuli, and it is broken down by
DEs (Lugnier, 2006). PDE1 is signiﬁcantly expressed in neuronsol (ETOH) or saline (SAL) from P2 (P1 = birth day) to P8 and treated with vinpocetine
t the neonatal exposure to ethanol increases locomotor activity in animals treated
comotor activity to the control levels. FLSD: *P < 0.05; **P  < 0.01.
of the hippocampus and cortex (Lugnier, 2006), which suggests
that this enzyme may  control cAMP levels in areas that are
markedly affected by ethanol exposure during the brain growth
spurt (Gil-Mohapel et al., 2010; Olney et al., 2002a).  Considering
that the cAMP/PKA signaling system is involved in the control of
a variety of cellular processes related with metabolism, gene tran-
scription and neurotransmission, it is difﬁcult to clearly identify
the mechanism(s) through which the cAMP/PKA cascade and the
ethanol-induced hyperactivity are linked.
One possibility is related to the fact that cAMP is a critical sec-
ond messenger involved in catecholaminergic transmission and
exerts its effects mainly through the PKA (Missale et al., 1998). Of
note, PKA plays a key role in the control of the catalytic activity
of tyrosine hydroxylase (TH), the rate-limiting enzyme in the cate-
cholamine biosynthesis. PKA acts by phosphorylating TH (Zigmond
et al., 1989) or CREB, which is the major transcript factor for TH gene
(Lewis-Tufﬁn et al., 2004). In the rat brain, the inhibition of PDE
stimulates TH activity (Kehr et al., 1985) and increases the release
of noradrenaline and dopamine in vitro (Schoffelmeer et al., 1985;
Yamashita et al., 1997). In addition, in spontaneously hypertensive
rats (SHR), a widely studied model for ADHD has demonstrated a
reduced expression of TH (King et al., 2000; Wu  et al., 2010). Based
on this evidence, it is possible that the impairment in the cAMP/PKA
cascade contributes to the reduction in the catecholaminergic func-
tion that, in turn, is strongly associated with the hyperactivity
phenotype (O’Malley and Nanson, 2002).
In addition to the well-documented role of catecholaminergic
dysfunction, other factors such as a deﬁcient ATP production may
play role in the pathophysiology of hyperactivity (Russell et al.,
2006). Interestingly, the administration of vinpocetine increases
ATP levels in the rat’s cortex (Rosdy et al., 1976) and in astrocyte
cultures (Gabryel et al., 2002). Finally, PDE1 inhibition caused by
vinpocetine has also been reported to promote elevation of cGMP
levels, which activates the cGMP-dependent protein kinase G (PKG)
(Medina, 2011b). Although there are no studies associating cGMP
levels and hyperactivity, it is not possible to discard that increased
cGMP level signiﬁcantly contributes to the vinpocetine-mediated
amelioration of hyperactivity in ethanol-treated animals.
Some studies have proposed the use of PDE inhibitors as neu-
ronal plasticity enhancers (Medina, 2011b; Navakkode et al., 2004;
Puzzo et al., 2008). Neuronal plasticity entails functional changes
in the efﬁcacy of excitatory and inhibitory connections (e.g., synap-
tic strength), structural changes in the shape and size of synapses
and in the physical connectivity of networks. Accordingly, vinpoce-
F. Nunes et al. / Drug and Alcohol De
Fig. 2. Mean (±SEM) of cAMP levels in the hippocampus (A) and in the cortex (B)
of  mice exposed to ethanol (ETOH) or saline (SAL) from P2 (P1 = birth day) to P8
and  treated with vinpocetine 20 mg/kg (Vp20 mg)  or vehicle (DMSO) at P30. The
treatment with vinpocetine increase cAMP levels both in the hippocampus and in
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genetics of attention-deﬁcit/hyperactivity disorder: an overview. Eur. Childhe cortex. In the hippocampus, ethanol elicited a decrease in cAMP levels, which
as  restored by vinpocetine treatment. FLSD: *P < 0.05; ***P < 0.001.
ine treatment has been shown to facilitate long-term potentiation
Molnar et al., 1994), to enhance the structural dynamics of den-
ritic spines (Lendvai et al., 2003), to improve learning/memory
n rats (DeNoble, 1987) and to enhance performance on cognitive
ests in humans (Kidd, 1999). It has been suggested that altered
xpression of genes, which results in reduced plasticity in the brain,
riggers molecular mechanisms responsible for the development
f psychopathological conditions involving hyperactivity, such as
DHD (Banaschewski et al., 2010; Jensen et al., 2009; Parkitna et al.,
010; Rapoport and Gogtay, 2008; Tsai, 2007). Interestingly, sev-
ral lines of evidence suggest that deﬁcits in neuronal plasticity
nderlie some of the neurobehavioral problems observed in FASD
Filgueiras et al., 2010; Krahe et al., 2009; Medina and Krahe, 2008;
aul et al., 2010; Puglia and Valenzuela, 2010). Taken together,
hese data suggest that neuronal plasticity deﬁcits may  also con-
ribute to the hyperactivity observed in FASD and ADHD and, in
his sense, the restorative effects of vinpocetine could be associated
ith its plasticity boosting properties.pendence 119 (2011) 81– 87 85
It is important to note that the restorative effects of vinpocetine
in FASD models have been demonstrated only for short periods
after treatment (Filgueiras et al., 2010; Krahe et al., 2009; Medina
et al., 2006). Therefore, whether the amelioration of the neu-
robehavioral deﬁcits induced by ethanol during development is
persistent remain to be investigated. Further studies in animal
models of FASD are also required to verify if the treatment with
vinpocetine has beneﬁcial effects on the other two core features
of ADHD: inattention and impulsivity. This issue is particularly
important since it was found that although children with FASD dis-
play more behavioral problems and difﬁculties with attention and
hyperactivity/impulsivity than typical children, attention deﬁcits
tend to account for more problems than hyperactive symptoms
(Kodituwakku et al., 2006). Additionally, the ADHD medication may
be less effective in treating the inattention symptom cluster in the
FASD population (Doig et al., 2008). Another question that should
be considered is that vinpocetine is already used (as Cavinton©)
in some countries to treat cerebrovascular-related diseases with-
out showing signiﬁcant side effects at doses ranging from 15 to
45 mg  per day (Kidd, 1999). Therefore, the safety and availability of
this drug make this compound a promising agent for future clinical
studies.
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